BioWorld

Dec. 21, 2006

View Archived Issues

Kosan, Pfizer In $250M Deal For Motilin Agonist Program

As Kosan Biosciences Inc. focuses on its cancer therapeutics, it licensed out its motilin agonist program to Pfizer Inc. in a worldwide deal worth up to $250 million in up-front and milestone payments. (BioWorld Today) Read More

PolyHeme Misses In Phase III Trauma Trial; Northfield Sinks

Read More

Genentech, Altus HGH Deal: Up To $280M For New Form

Read More

HHS Ends VaxGen's $877.5M Contract On Anthrax Vaccine

Read More

Panacos' Stock Tumbles On Pushback Of HIV Phase III

Read More

Orexigen Files IPO To Fund Its Obesity-Fighting Drugs

Read More

Other News To Note

Read More

Clinic Roundup

Read More